Yazarlar : Elstrom RL, Andemariam B, Martin P, Ruan J, Shore TB, Coleman M, Leonard JP, Furman RR.

Yayın : Leuk Lymphoma.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22263572

Konu : Lenfoma

Literatür İçeriği :  

Abstract

Abstract Patients with relapsed or refractory diffuse large B cell lymphoma may experience extended survival with second-line chemotherapy and autologous stem cell transplantation (ASCT). Since a major determinant of outcome after ASCT is responsiveness to second-line therapy, development of more effective second-line treatments is desirable. We investigated addition of bortezomib to rituximab, dexamethasone, ifosfamide, cisplatin and etoposide (VIPER). Fifteen patients were enrolled, of whom 7 were refractory to first line chemotherapy, and only 3 had maintained first response for one year. Nine (60%) patients achieved objective responses, of which 3 (20%) were IWC-PET complete responses. Median progression free survival was 3 months, and median overall survival was 10 months. At median follow up of 25 months, 5 patients (33%) remained alive. Treatment was well tolerated with no unexpected toxicity. Although response rates did not meet pre-defined criteria, activity was at least comparable to other second-line approaches despite a poor prognosis patient population.

Literatür Arşivi